Therapeutic antibody development company Patrys (ASX:PAB) has announced new pre-clinical data for its lead asset, PAT-DX1, from a study conducted by Professor Terrence Johns of the Telethon Kids Cancer Centre. …
Partrys' candidate in combination improves survival in brain cancer model
August 11, 2022 Australian Biotech
Latest Video
New Stories
-
HBF Run for a Reason is back after three year hiatus
October 3, 2022 - - Other Health -
Dietitians Australia calls for action on aged care weight loss
October 3, 2022 - - Other Health -
Private health insurers call for reform of second-tier default benefits
October 3, 2022 - - Other Health -
Australian company doses first patient in MND clinical trial
October 3, 2022 - - Latest News -
BMS welcomes expanded PBS listing for key immunotherapy
October 3, 2022 - - Latest News -
Introducing the first 'Week in Review' episode of 'The Dispatched Podcast'
September 30, 2022 - - Podcast -
TGA provisionally approves Pfizer’s COVID-19 vaccine for younger children
September 30, 2022 - - Latest News